Tocilizumab -- an interleukin (IL)-6 receptor inhibitor -- was approved by the FDA in 2017 for the treatment of severe or ...

During a Case-Based Roundtable® event, Ajay Nooka, MD, MPH, discussed adverse events related to talquetamab for multiple ...

Experts explore additional toxicities observed with B-cell maturation antigen–targeting bispecifics, such as infections, ...

Shares of Hoth Therapeutics HOTH surged 81.4% on Sept. 5, after the company announced positive data from the treatment of the ...

SAINT study is currently investigating intravenous trabectedin plus ipilimumab and nivolumab in the first line for advanced ...

Efavirenz is an important drug for treating HIV infection, but it has negative effects that can significantly impact patients ...

An unusual placebo effect in Aligos Therapeutics’ Phase IIa trial is driving shareholder skepticism for its metabolic ...

In an interview with Targeted Oncology, Mark R. Litzow, MD, discussed the incorporation of Immunotherapy into upfront acute ...

After missing primary endpoints in relapsing forms of MS, tolebrutinib has proved its efficacy in secondary progressive MS ...

Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

Application error: a client-side exception has occurred (see the browser console for more information).

Scorpion Therapeutics, Inc. (“Scorpion”), a pioneering clinical-stage oncology company dedicated to transforming the lives of ...